We Claim:

1. A process for preparing an oral dosage form containing modafinil, the process comprising:

forming a dosage form comprising

about 7% - 25% by weight of modafinil particles have diameters greater than 220 μm; and

about 75% - 93% by weight of modafinil particles have diameters less than 220 μm.

2. The process according to claim 1 wherein about 7% by weight of the modafinil particles have diameters greater than 220 μm and about 93% by weight of the modafinil particles have diameters less than 220 μm.

3. The process according to claim 1 wherein about 10% by weight of the modafinil particles have diameters greater than 220 μm and about 90% by weight of the modafinil particles have diameters less than 220 μm.

4. The process according to claim 1 wherein about 15% by weight of the modafinil particles have diameters greater than 220 μm and about 85% by weight of the modafinil particles have diameters less than 220 μm.

5. The process according to claim 1 wherein the specific surface area of the modafinil particles is at least 0.2 m^2/gm.

6. The process according to claim 1 wherein the dosage form releases at least 75% of the modafinil in about 45 minutes.

7. The process according to claim 1 wherein the dosage form comprises a tablet or a capsule.

8. The process according to claim 1 further comprising one or more pharmaceutically acceptable excipients.

9. The process according to claim 8 wherein the pharmaceutically acceptable excipients comprise one or more of binders, diluents, disintegrants, surfactants, lubricants, glidants, and coloring agents.

10. The process according to claim 1 wherein forming the dosage form comprises

blending the modafinil particles with one or more pharmaceutically inert excipients to form a blend,

granulating the blend to form granules,

blending the granules with one or more pharmaceutically inert excipients, and

compressing or filling into a solid dosage form.

11. The process according to claim 10 wherein granulating comprises wet granulation.

12. The process according to claim 10 wherein granulating comprises dry granulation.

13. The process according to claim 10 wherein the dosage form comprises a tablet and the process further comprises coating the tablet.

14. The process according to claim 1, wherein forming the dosage form comprises blending the modafinil particles with one or more pharmaceutically inert excipients to form a blend and compressing the blend or filling the blend into a solid dosage form.

15. The process according to claim 1 wherein forming a dosage form further comprises mixing the modafinil particles in geometric progression with one or more pharmaceutically acceptable excipients to form a blend.

16. The process according to claim 15 further comprising:

granulating the blend to form granules;

optionally drying the granules;

sizing the granules;

mixing the sized granules with one or more pharmaceutically acceptable excipients; and

compressing into a tablet.

17. An oral dosage form of modafinil comprising:

about 7% to 25% by weight of modafinil particles have diameters greater than 220 μm; and

about 93% to 75% by weight of modafinil particles have diameters less than 220 μm.

18. The oral dosage form according to claim 17 wherein about 7% by weight of the modafinil particles have diameters greater than 220 μm and about 93% by weight of the modafinil particles have diameters less than 220 μm.

19. The oral dosage form according to claim 17 wherein about 10% by weight of the modafinil particles have diameters greater than 220 μm and about 90% by weight of the modafinil particles have diameters less than 220 μm.

20. The oral dosage form according to claim 17 wherein about 15% by weight of the modafinil particles have diameters greater than 220 μm and about 85% by weight of the modafinil particles have diameters less than 220 μm.

21. The oral dosage form according to claim 17 wherein the specific surface area of the modafinil particles is at least 0.2 m^2/gm.

22. The oral dosage form according to claim 17 wherein the dosage form releases at least 75% of the modafinil in about 45 minutes.

23. The oral dosage form according to claim 17 wherein the dosage form comprises a tablet or capsule.

24. The oral dosage form according to claim 17 further comprising one or more pharmaceutically acceptable excipients.

25. The oral dosage form according to claim 24 wherein the pharmaceutically acceptable excipients comprises one or more of binders, diluents, disintegrants, surfactants, lubricants, glidants, and coloring agents.

26. A method of treating a condition using modafinil, the method of treating comprising:

providing an oral dosage form of modafinil comprising

about 7% to 25% by weight of modafinil particles have diameters greater than 220 μm; and

about 93% to 75% by weight of modafinil particles have diameters less than 220 μm.

27. The method according to claim 25 wherein about 7% by weight of the modafinil particles have diameters greater than 220 μm and about 93% by weight of the modafinil particles have diameters less than 220 μm.

28. The method according to claim 25 wherein about 10% by weight of the modafinil particles have diameters greater than 220 μm and about 90% by weight of the modafinil particles have diameters less than 220 μm.

29. The method according to claim 25 wherein about 15% by weight of the modafinil particles have diameters greater than 220 μm and about 85% by weight of the modafinil particles have diameters less than 220 μm.

30. The method according to claim 25 wherein the specific surface area of the total modafinil particles is at least 0.2 m^2/gm.

31. The method according to claim 25 wherein the dosage form releases at least 75% of the modafinil in about 45 minutes.

32. The method according to claim 25 wherein the dosage form comprises a tablet or capsule.

33. The method according to claim 25 further comprising one or more pharmaceutically acceptable excipients.

34. The method according to claim 33 wherein the pharmaceutically acceptable excipients comprise one or more of binders, diluents, disintegrants, surfactants, lubricants, glidants, and coloring agents.

35. The method according to claim 25 wherein the condition comprises one or more of narcolepsy and idiopathic hypersomnia.

36. An oral dosage form of modafinil comprising an intragranular portion and an extragranular portion:

the intragranular portion comprising about 7% to 25% by weight of modafinil particles having diameters greater than 220 μm, about 93% to 75% by weight of modafinil particles having diameters less than 220 μm, and one or more pharmaceutically acceptable excipients; and

the extragranular portion comprising one or more pharmaceutically acceptable excipients.

37. The oral dosage form according to claim 36 wherein the oral dosage form releases one or more of between 48% and 81% of the modafinil within 15 minutes, between 68% and 87% of the modafinil within 30 minutes, between 76% and 95% of the modafinil within 45 minutes, between 84% and 97% of the modafinil within 60 minutes, and between 89% and 98% of the modafinil within 90 minutes.

38. The oral dosage form according to claim 37 wherein the modafinil is released in a USP Apparatus II, in 900 ml of water, and stirred at 50 rpm.

39. The oral dosage form according to claim 36 wherein the oral dosage form is provided with labeling for one or more of wakefulness promotion, to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy, and idiopathic hypersomnia.